Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is quite busy. We plan to escort Mrs. Pharmalot to another installment of our “Let’s-see-them-before-they-die” concert series. We will also expose one of our short people to some ancient culture. Last, but certainly not least, we will attend synagogue. Neo-Nazis will not replace us. And what about you? Once again, we will point out this is a lovely time of year to enjoy the great outdoors. You could encourage folks to vote in the fascinating and important election that is nearing — on this side of the pond, anyway. Or you could simply make plans for the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Novo Nordisk (NVO) has raised the number of jobs that will be cut this year as the drug maker reallocates research and development spending amid pricing pressures in the U.S., its biggest market, The Wall Street Journal writes. In September, the company disclosed plans to shed around 400 workers, but now the total number of planned cuts has grown to 1,300 by the end of the year. About half of the job cuts are coming from commercial operations, while 400 jobs will be eliminated in the research and development unit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!